Overview
Diffuse leptomeningeal melanocytosis refers to the diffuse infiltration of melanin-producing cells within the leptomeninges, often seen in pediatric patients with neurocutaneous syndromes like Niemann-Pick disease type A or in metastatic spread from primary melanomas, though the provided abstracts focus more on leptomeningeal metastases from solid tumors 13.Diagnosis
Clinical Presentation: Neurological deficits, headaches, cranial nerve palsies, and altered mental status 1.
Imaging: MRI with gadolinium contrast is crucial for visualizing leptomeningeal enhancement 1.
Cerebrospinal Fluid (CSF) Analysis: Cytology for malignant cells or melanin-containing cells; elevated protein and decreased glucose levels may indicate metastatic involvement 1.
Diagnostic Criteria: Combination of clinical symptoms, imaging findings, and CSF analysis for definitive diagnosis 1.Management
First-Line Treatments:
- Intrathecal Chemotherapy: Commonly used, though specific drug classes and doses are not detailed in the abstracts 14.
- Systemic Chemotherapy: Tailored to the primary tumor type, aiming to control systemic disease and reduce leptomeningeal spread 1.
Adjunctive Treatments:
- Radiation Therapy:
- Focal Radiotherapy: For palliation of focal symptoms, pain, and CSF blockages 4.
- Craniospinal Irradiation (CSI): Used in high-risk patients or for symptom palliation, with median doses around 30 Gy 34.
- CSF Diversion: Shunting procedures for LM-associated hydrocephalus, though evidence for OS improvement is inconclusive 2.Special Populations
Pediatrics: Not explicitly addressed in the provided abstracts, but diffuse leptomeningeal melanocytosis is more commonly seen in pediatric populations with specific syndromes 1.
Comorbidities: Management considerations for comorbidities like hydrocephalus are noted, with CSF diversion procedures discussed 2.Key Recommendations
Use MRI with gadolinium contrast for definitive diagnosis of leptomeningeal metastases (Evidence: Moderate 1).
Consider intrathecal and systemic chemotherapy tailored to the primary tumor type (Evidence: Expert opinion 1).
Focal radiotherapy can provide significant palliation for focal symptoms and CSF blockages (Evidence: Moderate 4).
Craniospinal irradiation may be considered for high-risk patients or those with active disease, with median doses around 30 Gy (Evidence: Moderate 3).
CSF diversion procedures may be indicated for symptomatic hydrocephalus, though their impact on overall survival is uncertain (Evidence: Weak 2).References
1 Le Rhun E, Weller M, van den Bent M, Brandsma D, Furtner J, Rudà R et al.. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO open 2023. link
2 Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, Chari A, Hill CS, Thorne L. Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis. Neurosurgical focus 2023. link
3 Maillie L, Salgado LR, Lazarev S. A systematic review of craniospinal irradiation for leptomeningeal disease: past, present, and future. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021. link
4 Mehta M, Bradley K. Radiation therapy for leptomeningeal cancer. Cancer treatment and research 2005. link